Conference
Changes in treatment and outcomes of stage II/III rectal cancer patients treated with trimodality therapy (TT) between 2006-2016: An NCDB analysis.
Abstract
32
Background: Trimodality therapy (TT) remains standard for stage 2/3 rectal cancer and emerging evidence supports better outcomes with total neoadjuvant therapy (TNT) than similar therapy given post-operatively (Post-op). Real-world practice patterns and sequence of TT have significant implications on rectal cancer quality of care, outcomes and clinical trial design, and are not well described. Methods: The National Cancer …
Authors
Kennecke HF; Bahnson HT; Lin B; Kaplan J; Pham H; Suen A; Simianu V
Volume
39
Pagination
pp. 32-32
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
January 20, 2021
DOI
10.1200/jco.2021.39.3_suppl.32
Conference proceedings
Journal of Clinical Oncology
Issue
3_suppl
ISSN
0732-183X